Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock By Investing.com

Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (), sold 18,500 shares of the company’s Class A Common Stock on June 23, 2026, for a total value of $701,769. The shares were sold at prices ranging between $37.9311 and $38.43. The stock has since declined to $29.99, down 41% year-to-date, though InvestingPro analysis suggests the company is currently undervalued at these levels.

The sales were executed pursuant to a pre-arranged trading plan, known as a Rule 10b5-1(c) plan, which was adopted on January 9, 2026.

On the same day, Mr. Fordyce also exercised options to acquire 18,500 shares of Class A Common Stock at an exercise price of $2.8968 per share, totaling $53,590. These options had a vesting schedule where 1/4 of the shares vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.

Following these transactions, Mr. Fordyce directly holds 235,244 shares of Vera Therapeutics Class A Common Stock and 572,051 stock options. The company, valued at $2.16 billion, maintains a “Weak” financial health rating according to InvestingPro metrics, with analysts noting the biotech is quickly burning through cash. InvestingPro offers 7 additional exclusive tips for VERA investors seeking deeper insights into the company’s prospects.

In other recent news, Vera Therapeutics reported its second-quarter 2026 results, which were seen as largely uneventful by Goldman Sachs. The company’s operating expenses totaled $112 million, coming in 13% below Goldman Sachs’ estimate of $129 million. Vera Therapeutics posted a loss per share of $1.52, which was better than Goldman Sachs’ projection of $1.73. Meanwhile, Vera Therapeutics announced the accelerated FDA approval of its drug, Trutakna (atacicept), for IgA nephropathy, with a planned launch in the coming weeks. Following this approval, Guggenheim raised its price target for Vera Therapeutics to $76 from $56, maintaining a Buy rating, while Cantor Fitzgerald reiterated an Overweight rating with a $100 price target. In personnel changes, Nancy Boman will take over as chief regulatory officer as William Turner transitions to a strategic advisor role. Additionally, H.C. Wainwright reduced its price target on Vera Therapeutics to $90 from $125, citing competition and adjusting its peak penetration rate assumption for atacicept. Lastly, Goldman Sachs adjusted its price target on Vera Therapeutics shares to $80 from $90, maintaining a Buy rating.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.